Amgen Inc. is in advanced talks to buy drug company Horizon Therapeutics PLC, according to people familiar with the matter,likely to be valued at well over $20 billion and mark the largest healthcare merger of the year.
The U.S. biotechnology company was the last of three suitors standing in an auction for Horizon, the people said, after French drugmaker Sanofi SA said Sunday it was out of the running.
Uno de los puntos negativos es que Amgen incrementaría su deuda de 1,5x a cerca de 3x deuda/ebitda.
Amgen esta pagando un per15 para una biotech que crece al 20% y tiene caja neta
OJO: Amgen dispuesta a comprar Horizon por 20B. Es una adquisición de peso (una de las mayores de los últimos años).La adquisición le daría a Amgen acceso al pipeline de Horizon para enfermedades raras autoinmunes e inflamatorias, incluido su exitoso tratamiento Tepezza.
The people of the world hear our voice👊🏻 Iranian people are fighting against the dictator Support the people of Iran💚🤍❤️ IranRevolution Iran
Stock Options
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: JaxBizJournal - 🏆 599. / 51 Read more »
Source: JaxBizJournal - 🏆 599. / 51 Read more »
Source: JaxBizJournal - 🏆 599. / 51 Read more »